纳米药物在放射性肺损伤治疗中的研究进展

放射性肺损伤是胸部恶性肿瘤放射治疗、核事故重症损伤的常见并发症,目前仍缺乏有效治疗手段。近年来纳米技术的发展给这一问题的解决带来了希望。纳米药物是指晶体或载体粒径在1-100 nm范围内的药物颗粒,可以通过本身物理特性或者靶向载药系统改善药代动力学,增加药物在靶器官的分布,从而减轻放射性肺炎和肺纤维化症状,为放射性肺损伤的临床治疗提供了新思路和新途径。本文就近年来纳米药物在放射性肺损伤治疗中的相关进展进行综述。

Advances in the treatment of radiation-induced lung injury with nanomedicine

Radiation-induced lung injury is a common complication of radiotherapy for thoracic tumors and injuries from nuclear accidents. Effective treatments are urgently required. Development of nanotechnology in recent years brings hope to the solution of this problem. Nanomedicine is a crystal or carrier with size in the range of 1-100 nm, which can improve pharmacokinetics and increase the biodistribution of therapeutic agents to the target organs. These advantages can provide a new perspective for clinical treatment. This article reviews the relevant progress in recent years.